Chartwell Retirement Residences (CSH.UN) Fair Value Analysis (2026)

Executive Summary

Based on its current valuation metrics, Chartwell Retirement Residences (CSH.UN) appears significantly overvalued. As of October 26, 2025, with a stock price of $20.90, the company trades at demanding multiples, including a high trailing Price to Funds From Operations (P/FFO) of approximately 25.6x and an EV/EBITDA of 27.05x, which are elevated for the healthcare REIT sector. The dividend yield of 2.93% is modest and near its 10-year low, further suggesting the stock is expensive relative to its historical norms and peer group. The stock is trading at the top of its 52-week range, indicating strong recent performance but limited near-term upside. The overall takeaway for investors is negative, as the current market price seems to have outpaced the company's intrinsic value based on fundamental analysis.

Comprehensive Analysis

As of October 26, 2025, Chartwell Retirement Residences (CSH.UN) closed at a price of $20.90. A comprehensive valuation analysis suggests this price is well above its estimated intrinsic value, pointing to an overvalued stock with a limited margin of safety for potential investors. With a current price of $20.90 versus a fair value estimate of $13.00–$15.00, the stock appears to have a potential downside of around 33.0%, leading to an Overvalued verdict and making it an unattractive entry point. A key valuation tool for REITs is the Price to Funds From Operations (P/FFO) ratio. Based on an estimated Trailing Twelve Month (TTM) FFO per share of $0.82, Chartwell trades at a P/FFO of 25.6x. This is considerably higher than the typical historical range of 12x to 18x for healthcare REITs. Similarly, its EV/EBITDA multiple of 27.05x is elevated compared to the industry norm of 8x-12x. Applying a more reasonable P/FFO multiple of 16x-18x to its TTM FFO per share suggests a fair value range of $13.12–$14.76. Chartwell's current dividend yield is 2.93%. This is near its 10-year low and below the median yield of 4.19% over the last 13 years, signaling that the stock price is high relative to its dividend payout. While the dividend is supported by cash flow, with a reasonable FFO payout ratio between 46% and 58% in recent periods, the low starting yield offers little appeal for income-focused investors. A simple dividend discount model would estimate the fair value at approximately $12.44, reinforcing the overvaluation thesis. The company trades at a Price/Book (P/B) ratio of 5.0x, a significant premium to its underlying accounting book value. While Net Asset Value (NAV) is a more precise metric for REITs, a P/B ratio this high is a strong indicator that the market price has detached from the tangible asset value. In summary, all three valuation methods point toward a similar conclusion: the multiples and dividend-based approaches triangulate to a fair value estimate of $13.00 – $15.00, which is substantially below the current trading price.

Factor Analysis

Dividend Yield And Cover

Fail

The dividend yield is low compared to historical averages and the broader Canadian market, and growth has been negligible, making it unattractive despite a sustainable payout ratio.

Chartwell’s dividend yield of 2.93% is modest and sits near its 10-year low. This is significantly less attractive than the top 25% of dividend payers in the Canadian market, which yield around 5.82%. While the dividend is higher than the bottom quarter of the market, it offers little premium for the risks associated with an individual stock. On a positive note, the dividend appears sustainable. The FFO payout ratio has been healthy, recorded at 45.93% in Q2 2025 and 58.43% for the full year 2024. This means the dividend is well-covered by the cash flow from operations, which is a crucial health metric for a REIT. However, the 5-year dividend growth rate is a mere 0.40%, indicating payouts have been nearly flat. For a valuation analysis, a low and stagnant yield is a strong signal of overvaluation, failing to compensate investors adequately.

EV/EBITDA And P/B Check

Fail

The stock's Enterprise Value to EBITDA and Price to Book ratios are extremely high, indicating a significant premium compared to both industry benchmarks and the company's tangible asset base.

Chartwell’s valuation appears stretched on asset and enterprise value multiples. The current EV/EBITDA ratio (TTM) is 27.05x. This is substantially higher than typical valuation ranges for Canadian healthcare facilities, which are generally between 8-12x EBITDA. This high multiple suggests the market is pricing in exceptionally optimistic growth and profitability that may not materialize. Furthermore, the Price/Book ratio of 5.0x is a major red flag, showing a large disconnect between the market price and the net accounting value of its assets. Adding to the concern is the high leverage, with a Debt/EBITDA ratio of 8.42x, which heightens the risk profile. These metrics collectively point to a company whose market valuation has far exceeded its fundamental and asset-based worth.

Growth-Adjusted FFO Multiple

Fail

The stock trades at a very high Price to FFO multiple that is not justified by available forward-looking growth estimates, suggesting the price has outrun its earnings potential.

Valuing a REIT based on its Funds From Operations (FFO) is standard practice. Chartwell's estimated TTM P/FFO ratio is 25.6x, calculated from a 20.90 price and $0.82 TTM FFO per share. This multiple is significantly elevated for a mature healthcare REIT. While the company has shown recent occupancy recovery and revenue growth, this appears to be more than fully priced into the stock. Data on specific forward FFO growth projections is limited in the provided information, but the forward P/E ratio of 97.21 also points to extremely high expectations. Without clear, robust, and sustained double-digit FFO growth forecasts to support such a high multiple, the stock fails a growth-adjusted valuation test. The current valuation demands a level of future growth that seems unlikely for a company in this sector.

Multiple And Yield vs History

Fail

The current dividend yield is near a 10-year low while its valuation multiples are likely at a peak, indicating the stock is expensive compared to its own historical valuation trends.

Comparing a stock to its own history provides crucial context. Chartwell’s current dividend yield of 2.93% is close to its 10-year low and well below its 13-year median yield of 4.19%. This is a classic sign that the stock price has appreciated much faster than its dividend payments, making it historically expensive on a yield basis. While specific 5-year average P/FFO data was not found, the fact that the stock is trading at the very top of its 52-week range ($14.71 to $21.08) strongly implies that its current P/FFO multiple of ~25.6x is also well above its historical average. Stocks tend to revert to their mean valuation over time, and trading at such a significant premium to historical norms presents a poor risk-reward proposition.

Price to AFFO/FFO

Fail

The Price to FFO and AFFO ratios are elevated, resulting in a low cash flow yield for the investor, which suggests the stock is overpriced relative to the actual cash earnings it generates.

Price to Funds From Operations (P/FFO) and Price to Adjusted Funds From Operations (P/AFFO) are the most critical valuation metrics for REITs. Based on a TTM FFO per share of $0.82, Chartwell’s P/FFO is 25.6x. The provided data indicates AFFO is the same as FFO, so the P/AFFO is also 25.6x. These multiples are high for the healthcare REIT industry, which typically trades in a lower range. An alternative way to view this is the FFO Yield (the inverse of P/FFO), which is just 3.9% ($0.82 / $20.90). This represents a low cash-flow return to the investor at the current price, especially before accounting for the capital needed to maintain properties. This low yield, coupled with the high multiple, fails to offer a compelling value proposition.